Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer

被引：0

作者：

Lin, Jessica Jiyeong

Tan, Daniel Shao-Weng

Kummar, Shivaani

Patel, Jyoti D.

Cermignani, Luciano

Dai, Ming-Shen

Lassen, Ulrik Niels

Leyvraz, Serge

Liu, Yongmei

Moreno, Victor

Rosen, Lee S.

Saada-Bouzid, Esma

Solomon, Benjamin Maurice

Xu, Rui-Hua

Yachnin, Jeffrey

Norenberg, Ricarda

Burcoveanu, Domnita-Ileana

Mussi, Chiara E.

Shen, Lin

Drilon, Alexander E.

机构：

[1] Massachusetts Gen Hosp, Dept Med, Boston, MA USA

[2] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[3] Duke NUS Med Sch, Singapore, Singapore

[4] Oregon Hlth & Sci Univ, Portland, OR USA

[5] Northwestern Univ, Chicago, IL USA

[6] Hosp Aleman, Buenos Aires, Argentina

[7] Tri Serv Gen Hosp, Taipei, Taiwan

[8] Rigshosp, Dept Oncol, Copenhagen, Denmark

[9] Charite Univ Med Berlin, Berlin, Germany

[10] Sichuan Univ, West China Hosp, Canc Ctr, Chengdu, Peoples R China

[11] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China

[12] START MADRID FJD, Hosp Fdn Jimenez Diaz, Madrid, Spain

[13] UCLA, Div Hematol Oncol, Santa Monica, CA USA

[14] Univ Cote Dazur, Ctr Antoine Lacassagne, Nice, France

[15] Avera Canc Inst, Sioux Falls, SD USA

[16] Sun Yat Sen Univ, State Key Lab, Canc Ctr, Guangzhou, Peoples R China

[17] Karolinska Univ Hosp, Stockholm, Sweden

[18] Chrestos Concept GmbH & Co KG, Essen, Germany

[19] Bayer Healthcare Pharmaceut Inc, Basel, Switzerland

[20] Bayer SpA, Milan, Italy

[21] Peking Univ, Key Lab Carcinogenesis & Translat Res, Dept Gastrointestinal Oncol, Minist Educ Beijing,Canc Hosp & Inst, Beijing, Peoples R China

[22] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9056

引用

页数：1

共 50 条

[21] EFFICACY AND SAFETY OF LAROTRECTINIB IN PEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE CANCER: AN EXPANDED DATASET
Koga, Yuhki
PEDIATRIC BLOOD & CANCER, 2022, 69
[22] EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER: AN EXTENDED FOLLOW-UP
Zwaan, C. Michel
Van Tilburg, Cornelis
Doz, Francois
Albert, Catherine
Blattmann, Claudia
Geoerger, Birgit
Dubois, Steven
Federman, Noah
Mascarenhas, Leo
Nagasubramanian, Rama
Pappo, Alberto
Watt, Tanya
Norenberg, Ricarda
Dima, Laura
De la Cuesta, Esther
Laetsch, Theodore
Xu, Ruihua
PEDIATRIC BLOOD & CANCER, 2022, 69 : S324 - S325
[23] Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.
Hong, David S.
Shen, Lin
van Tilburg, Cornelis Martinus
Tan, Daniel Shao-Weng
Kummar, Shivaani
Lin, Jessica Jiyeong
Doz, Francois P.
McDermott, Raymond S.
Albert, Catherine M.
Berlin, Jordan
Bielack, Stefan S.
Lassen, Ulrik Niels
Tahara, Makoto
Norenberg, Ricarda
Shurshalina, Anna
Fellous, Marc Mardoche
Nogai, Hendrik
Xu, Rui-hua
Laetsch, Theodore Willis
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[24] Long-term efficacy and genomic characteristics of patients with TRK fusion lung cancer treated with larotrectinib
Moreno Garcia, V.
Lin, J.
Patel, J.
Lassen, U.
Solomon, B.
Rosen, L.
Leyvraz, S.
Tan, D. S. W.
Reeves, J. A.
Beckmann, G.
Rudolph, M.
Wierzbinska, J.
Dima, L.
Brega, N.
Kummar, S.
Drilon, A.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S786 - S787
[25] LONG-TERM EFFICACY AND SAFETY OF LAROTRECTINIB IN PAEDIATRIC PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION-POSITIVE PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMOURS
Nysom, Karsten
Doz, Francois
Geoerger, Birgit
Ora, Ingrid
Perreault, Sebastien
Norenberg, Ricarda
Fellous, Marc
De La Cuesta, Esther
Laetsch, Theodore W.
van Tilburg, Cornelis M.
NEURO-ONCOLOGY, 2022, 24 : 64 - 64
[26] Efficacy and safety of larotrectinib (laro) as first-line treatment for patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer
Hong, D. S.
Xu, R-H.
McDermott, R. S.
Shen, L.
Dierselhuis, M. P.
Doz, F.
Tahara, M.
Bernard-Gauthier, V.
Norenberg, R.
Brega, N.
Laetsch, T. W.
Drilon, A.
ANNALS OF ONCOLOGY, 2023, 34 : S469 - S469
[27] Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
Mascarenhas, Leo
van Tilburg, Cornelis Martinus
Zwaan, Francois Doz C. Michel
Albert, Catherine M.
Blattman, Claudia
Geoerger, Birgit
DuBois, Steven G.
Federman, Noah
Nagasubramanian, Ramamoorthy
Pappo, Alberto S.
Watt, Tanya Carens
Norenberg, Ricarda
Fellous, Marc Mardoche
De la Cuesta, Esther A.
Laetsch, Theodore Willis
Xu, Rui-Hua
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[28] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers
Drilon, Alexander
Tan, Daniel S. W.
Lassen, Ulrik N.
Leyvraz, Serge
Liu, Yongmei
Patel, Jyoti D.
Rosen, Lee
Solomon, Benjamin
Norenberg, Ricarda
Dima, Laura
Brega, Nicoletta
Shen, Lin
Moreno, Victor
Kummar, Shivaani
Lin, Jessica J.
JCO PRECISION ONCOLOGY, 2022, 6
[29] Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas
Kummar, Shivaani
Shen, Lin
Hong, David S.
McDermott, Ray
Keedy, Vicki L.
Casanova, Michela
Demetri, George D.
Dowlati, Afshin
Melcon, Soledad Gallego
Lassen, Ulrik N.
Leyvraz, Serge
Liu, Tianshu
Moreno, Victor
Patel, Jyoti
Patil, Tejas
Mallick, Atrayee Basu
Sousa, Nuno
Tahara, Makoto
Ziegler, David S.
Norenberg, Ricarda
Arvis, Pierre
Brega, Nicoletta
Drilon, Alexander
Tan, Daniel S. W.
CANCER, 2023, 129 (23) : 3772 - 3782
[30] Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer with an extended follow-up
McDermott, R. S.
van Tilburg, C.
Lin, J. J.
Kummar, S.
Tan, D. S. W.
Albert, C. M.
Berlin, J. D.
Lassen, U. N.
Doz, F.
Geoerger, B.
Mascarenhas, L.
Federman, N.
Norenberg, R.
Dima, L.
Mussi, C.
De La Cuesta, E. A.
Laetsch, T.
Hong, D. S.
Drilon, A. E.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S751 - S752

← 1 2 3 4 5 →